Academic Journal
Focal Unspecific Bone Uptake on [18F]PSMA-1007 PET: Evaluation Analog PROMISE Criteria and Validation via PET/CT Follow-Up
| العنوان: | Focal Unspecific Bone Uptake on [18F]PSMA-1007 PET: Evaluation Analog PROMISE Criteria and Validation via PET/CT Follow-Up |
|---|---|
| المؤلفون: | Jonas-Alexander Benecke, Eduardo Calderón, Gerald Reischl, Andreas Brendlin, Igor Tsaur, Christian la Fougère, Jonas Vogel |
| المصدر: | Diagnostics, Vol 14, Iss 20, p 2327 (2024) |
| بيانات النشر: | MDPI AG, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Medicine (General) |
| مصطلحات موضوعية: | prostate cancer, [18F]PSMA-1007, PET/CT, unspecific bone uptake, bone lesion, bone metastases, Medicine (General), R5-920 |
| الوصف: | Background: Focal unspecific bone uptake (UBU) is common in [18F]PSMA-1007 PET/CT, yet its clinical significance remains unclear, causing uncertainty in treatment decisions. Material and Methods: We retrospectively analyzed 99 prostate cancer patients (age 69 ± 7) who underwent [18F]PSMA-1007 PET/CT scans (3 MBq/kg; uptake time 70 ± 14 min) for staging and follow-up (after 13.0 ± 7.2 months). Semiquantitative assessment using the miPSMA score, analogous to the PROMISE criteria, evaluated the prevalence of UBU and bone metastases. Results: In the initial PET/CT scan, 56 patients had 230 lesions classified as UBU. A total of 19 patients were found to have bone metastases and UBU, while 24 patients had no focal bone uptake. UBU distribution was as follows: ribs (50%), spine (30%), pelvis (15%), and other sites (5%). There were no significant differences in age, Gleason score, injected tracer dose, uptake time, SUVpeak of UBU, or SUVmean in the spleen and parotid gland between patients with and without UBU. Follow-up showed stable miPSMA-score and CT appearance in 44/56 patients with UBU (79%), minor changes in 5/56 patients (8%), and new bone metastases in 7/56 patients (12%). Patient-specific analysis indicated at least one bone metastasis initially classified as UBU in 3/56 patients (5%) and new bone metastases in 4/56 patients (7%). In total, 4 of the 24 patients (17%) without initial focal uptake developed osseous metastases at follow-up. Conclusions: No significant differences were found between patients with or without UBU. Only a small portion of UBU (2%) evolved into metastases, a lower rate than the development of new osseous metastases, which appears to be independent of UBU. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2075-4418 96899247 |
| Relation: | https://www.mdpi.com/2075-4418/14/20/2327; https://doaj.org/toc/2075-4418 |
| DOI: | 10.3390/diagnostics14202327 |
| URL الوصول: | https://doaj.org/article/240ebf96899247b3bc13e1cec39f002d |
| رقم الانضمام: | edsdoj.240ebf96899247b3bc13e1cec39f002d |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20754418 96899247 |
|---|---|
| DOI: | 10.3390/diagnostics14202327 |